Åse Hagen M.
- Country
- Norway
- Department
- Neurology
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Asundexian for Ischemic Stroke Prevention in Adults Post-Acute Non-Cardioembolic Stroke or High-Risk TIA
- A Multicenter Non-Inferiority Trial Comparing Rituximab and Ocrelizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis Aged 18-60 Years
Data & Insights
Has run more than one trial at 71 of 380 partner sites.
Specializations
Neurological Disorders
The investigator specializes in treating multiple sclerosis, with particular focus on evaluating therapeutic approaches for relapsing-remitting MS. Their research extends to comparative studies of different treatment modalities in active MS cases.
- Multiple Sclerosis Management
- Immunotherapy Evaluation
- Relapsing MS Treatment
Neurodegenerative Conditions
The investigator conducts research in amyotrophic lateral sclerosis (ALS), focusing on innovative therapeutic approaches to slow disease progression. Their work includes evaluation of novel treatments compared to established therapies.
- ALS Treatment Development
- Disease Progression Markers
- Therapeutic Efficacy Assessment
Cerebrovascular Medicine
The investigator focuses on preventing ischemic stroke and managing transient ischemic attacks. Their research includes investigation of antithrombotic therapies and preventive treatments for patients with cerebrovascular conditions.
- Stroke Prevention
- Post-Stroke Care
- Antithrombotic Therapy
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.